Cancer Research and Treatment

Original Articles

Treatment Patterns and Changes in Quality of Life during First-Line Palliative Chemotherapy in Korean Patients with Advanced Gastric Cancer: Jin Won Kim, Jong Gwang Kim, Byung Woog Kang, Ik-Joo Chung, Young Seon Hong, Tae-You Kim, Hong Suk Song, Kyung Hee Lee, Dae Young Zang, Yoon Ho Ko, Eun-Kee Song, Jin Ho Baek, Dong‐Hoe Koo, So Yeon Oh, Hana Cho, Keun-Wook Lee; Cancer Res Treat. 2019;51(1):223-239. Published online October 19, 2018; DOI: https://doi.org/10.4143/crt.2018.073

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to evaluate chemotherapy patterns and changes in quality of life (QOL) during first-line palliative chemotherapy for Korean patients with unresectable or metastatic/recurrent gastric cancer (GC).
Materials and Methods
Thiswas a non-interventional, multi-center, prospective, observational study of 527 patients in Korea. QOL assessments were conducted using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaires (QLQ)-C30 and QLQ-STO22 every 3 months over a 12-month period during first-line palliative chemotherapy. The specific chemotherapy regimens were selected by individual clinicians.
Results
Most patients (93.2%) received combination chemotherapy (mainly fluoropyrimidine plus platinum) as their first-line palliative chemotherapy. The median progression-free survival and overall survival were 8.2 and 14.8 months, respectively. Overall, “a little” changes (differences of 5-10 points from baseline)were observed in some of the functioning or symptom scales; none of the QOL scales showed either “moderate” or “very much” change (i.e., ≥ 11 point difference from baseline). When examining the best change in each QOL domain from baseline, scales related to some aspects of functioning, global health status/QOL, and most symptoms revealed significant improvements (p < 0.05). Throughout the course of first-line palliative chemotherapy, most patients’ QOL was maintained to a similar degree, regardless of their actual response to chemotherapy.
Conclusion
This observational study provides important information on the chemotherapy patterns and QOL changes in Korean patientswith advanced GC. Overall, first-line palliative chemotherapy was found to maintain QOL, and most parameters showed an improvement compared with the baseline at some point during the course.

Citations

Citations to this article as recorded by

Health-related quality of life with bemarituzumab plus mFOLFOX6 in patients with FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer
Z.A. Wainberg, P.C. Enzinger, S. Qin, K. Yamaguchi, J. Wang, X. Zhou, A. Gnanasakthy, K. Taylor, A. Yusuf, I. Majer, A. Jamotte, Y.-K. Kang
ESMO Gastrointestinal Oncology.2024; 6: 100095. CrossRef
Impact of systemic cancer treatment on quality of life and mental well-being: a comparative analysis of patients with localized and advanced cancer
Adán Rodríguez-Gonzalez, Alberto Carmona-Bayonas, Raquel Hernandez San Gil, Patricia Cruz-Castellanos, Mónica Antoñanzas-Basa, David Lorente-Estelles, María Jose Corral, Manuel González-Moya, Oscar Alfredo Castillo-Trujillo, Emilio Esteban, Paula Jiménez-
Clinical and Translational Oncology.2023; 25(12): 3492. CrossRef
Reminiscence therapy-based care program alleviates anxiety and depression, as well as improves the quality of life in recurrent gastric cancer patients
Xing Wu, Weiwei Zhang
Frontiers in Psychology.2023;[Epub] CrossRef
Toxicities and Quality of Life during Cancer Treatment in Advanced Solid Tumors
Eun Mi Lee, Paula Jiménez-Fonseca, Rocio Galán-Moral, Sara Coca-Membribes, Ana Fernández-Montes, Elena Sorribes, Esmeralda García-Torralba, Laura Puntí-Brun, Mireia Gil-Raga, Juana Cano-Cano, Caterina Calderon
Current Oncology.2023; 30(10): 9205. CrossRef
Psychosocial functioning in individuals with advanced oesophago-gastric cancer: a mixed methods systematic review
Cara Ghiglieri, Martin Dempster, Sam Wright, Lisa Graham-Wisener
BMC Palliative Care.2023;[Epub] CrossRef
Multicenter phase III trial of S-1 and cisplatin versus S-1 and oxaliplatin combination chemotherapy for first-line treatment of advanced gastric cancer (SOPP trial)
Keun-Wook Lee, Ik-Joo Chung, Min-Hee Ryu, Young Iee Park, Byung-Ho Nam, Ho-Suk Oh, Kyung Hee Lee, Hye Sook Han, Bong-Gun Seo, Jae-Cheol Jo, Hyo Rak Lee, Jin Won Kim, Sook Ryun Park, Sang Hee Cho, Yoon-Koo Kang
Gastric Cancer.2021; 24(1): 156. CrossRef
Effect of early tumor response on the health-related quality of life among patients on second-line chemotherapy for advanced gastric cancer in the ABSOLUTE trial
Kazumasa Fujitani, Kohei Shitara, Atsuo Takashima, Keisuke Koeda, Hiroki Hara, Norisuke Nakayama, Shuichi Hironaka, Kazuhiro Nishikawa, Yutaka Kimura, Kenji Amagai, Hisashi Hosaka, Yoshito Komatsu, Ken Shimada, Ryohei Kawabata, Hideki Ohdan, Yasuhiro Kode
Gastric Cancer.2021; 24(2): 467. CrossRef
Quality-of-Life Assessment in Patients Receiving Palliative Chemotherapy: Call for Action
Maheswari Senthil
Annals of Surgical Oncology.2021; 28(1): 7. CrossRef
Impact of gastric cancer treatment on quality of life of patients
Kerstin Schütte, Christian Schulz, Kristina Middelberg-Bisping
Best Practice & Research Clinical Gastroenterology.2021; 50-51: 101727. CrossRef
Influencing Factors and Effects of Treatment on Quality of Life in Patients With Gastric Cancer—A Systematic Review
Sophia Kristina Rupp, Andreas Stengel
Frontiers in Psychiatry.2021;[Epub] CrossRef
Chronological changes in quality of life and body composition after gastrectomy for locally advanced gastric cancer
Ki Bum Park, Ji Yeon Park, Seung Soo Lee, Ho Young Chung, Oh Kyoung Kwon
Annals of Surgical Treatment and Research.2020; 98(5): 262. CrossRef
Viennese risk prediction score for Advanced Gastroesophageal carcinoma based on Alarm Symptoms (VAGAS score): characterisation of alarm symptoms in advanced gastro-oesophageal cancer and its correlation with outcome
Hannah Christina Puhr, Eleonore Pablik, Anna Sophie Berghoff, Gerd Jomrich, Sebastian Friedrich Schoppmann, Matthias Preusser, Aysegül Ilhan-Mutlu
ESMO Open.2020; 5(2): e000623. CrossRef

11,396 View
235 Download
12 Web of Science
12 Crossref

A Case-Control Study to Identify Risk Factors for Totally Implantable Central Venous Port-Related Bloodstream Infection: Guk Jin Lee, Sook Hee Hong, Sang Young Roh, Sa Rah Park, Myung Ah Lee, Hoo Geun Chun, Young Seon Hong, Jin Hyoung Kang, Sang Il Kim, Youn Jeong Kim, Ho Jong Chun, Jung Suk Oh; Cancer Res Treat. 2014;46(3):250-260. Published online July 15, 2014; DOI: https://doi.org/10.4143/crt.2014.46.3.250

Abstract PDF PubReader ePub

Purpose
To date, the risk factors for central venous port-related bloodstream infection (CVPBSI) in solid cancer patients have not been fully elucidated. We conducted this study in order to determine the risk factors for CVP-BSI in patients with solid cancer.
Materials and Methods
A total of 1,642 patients with solid cancer received an implantable central venous port for delivery of chemotherapy between October 2008 and December 2011 in a single center. CVP-BSI was diagnosed in 66 patients (4%). We selected a control group of 130 patients, who were individually matched with respect to age, sex, and catheter insertion time.
Results
CVP-BSI occurred most frequently between September and November (37.9%). The most common pathogen was gram-positive cocci (n=35, 53.0%), followed by fungus (n=14, 21.2%). Multivariate analysis identified monthly catheter-stay as a risk factor for CVP-BSI (p=0.000), however, its risk was lower in primary gastrointestinal cancer than in other cancer (p=0.002). Initial metastatic disease and long catheter-stay were statistically significant factors affecting catheter life span (p=0.005 and p=0.000). Results of multivariate analysis showed that recent transfusion was a risk factor for mortality in patients with CVP-BSI (p=0.047).
Conclusion
In analysis of the results with respect to risk factors, prolonged catheter-stay should be avoided as much as possible. It is necessary to be cautious of CVP-BSI in metastatic solid cancer, especially non-gastrointestinal cancer. In addition, avoidance of unnecessary transfusion is essential in order to reduce the mortality of CVP-BSI. Finally, considering the fact that confounding factors may have affected the results, conduct of a well-designed prospective controlled study is warranted.

Citations

Citations to this article as recorded by

Risk Factors of the Totally Implantable Venous Access Device-Related Infection in Patients With Brain Tumors Undergoing Chemotherapy After Surgery
Haihong Li, Jing Shan
Surgical Infections.2024; 25(2): 133. CrossRef
An analysis of totally implantable central venous port system infections in an urban tertiary referral center
Ulrich Krümpelmann, Ahmed Boseila, Mathias Löhnert, Olaf Kaup, Jacob J. Clarenbach, Martin Görner
Journal of Chemotherapy.2021; 33(4): 228. CrossRef
Use of catheter with 2-methacryloyloxyethyl phosphorylcholine polymer coating is associated with long-term availability of central venous port
Yuuki Iida, Kumiko Hongo, Takanobu Onoda, Yusuke Kita, Yukio Ishihara, Naoki Takabayashi, Ryo Kobayashi, Takeyuki Hiramatsu
Scientific Reports.2021;[Epub] CrossRef
Clinical Characteristics and Risk Factors of Long-term Central Venous Catheter–associated Bloodstream Infections in Children
Hye Min Moon, Suji Kim, Ki Wook Yun, Hyun-young Kim, Sung Eun Jung, Eun Hwa Choi, Hoan Jong Lee
Pediatric Infectious Disease Journal.2018; 37(5): 401. CrossRef
Risk factors for health care–associated infection in hospitalized adults: Systematic review and meta-analysis
Alba Luz Rodríguez-Acelas, Miriam de Abreu Almeida, Bruna Engelman, Wilson Cañon-Montañez
American Journal of Infection Control.2017; 45(12): e149. CrossRef
WITHDRAWN: Prevention of peripherally inserted central catheter-related infections in very low-birth-weight infants by using a central line bundle guideline with a standard checklist
Chen Yuan, Qing Zhao, Xiaoyan Song, Fei Meng
International Journal of Nursing Sciences.2016; 3(1): 50. CrossRef
Prevention of peripherally inserted central line-associated blood stream infections in very low-birth-weight infants by using a central line bundle guideline with a standard checklist: a case control study
Wei Wang, Chunling Zhao, Qinglian Ji, Ying Liu, Guirong Shen, Lili Wei
BMC Pediatrics.2015;[Epub] CrossRef
Central venous access in oncology: ESMO Clinical Practice Guidelines
B. Sousa, J. Furlanetto, M. Hutka, P. Gouveia, R. Wuerstlein, J.M. Mariz, D. Pinto, F. Cardoso
Annals of Oncology.2015; 26: v152. CrossRef
Port type is a possible risk factor for implantable venous access port-related bloodstream infections and no sign of local infection predicts the growth of gram-negative bacilli
Jui-Feng Hsu, Hsu-Liang Chang, Ming-Ju Tsai, Ying-Ming Tsai, Yen-Lung Lee, Pei-Huan Chen, Wen-Chieh Fan, Yu-Chung Su, Chih-Jen Yang
World Journal of Surgical Oncology.2015;[Epub] CrossRef

13,284 View
119 Download
11 Web of Science
9 Crossref

Trends in the Aggressiveness of End-of-Life Care for Advanced Stomach Cancer Patients: Ji Hyung Hong, Sang-Young Rho, Young Seon Hong; Cancer Res Treat. 2013;45(4):270-275. Published online December 31, 2013; DOI: https://doi.org/10.4143/crt.2013.45.4.270

Abstract PDF PubReader ePub

PURPOSE
It is important to balance the appropriateness of active cancer treatments and end-of-life care to improve the quality of life for terminally ill cancer patients. This study describes the treatment patterns and end-of-life care in terminal gastric cancer patients.
MATERIALS AND METHODS
We retrospectively analyzed the records of 137 patients with advanced gastric cancer receiving chemotherapy and dying between June 1, 2006 and May 31, 2011. We recorded interval between last chemotherapy dose and death; frequency of emergency room visits or admission to the intensive care unit in the last month before death; rate of hospice referral and agreement with written do-not-resuscitate orders; and change in laboratory values in the last three months before death.
RESULTS
During the last six months of life, 130 patients (94.9%) received palliative chemotherapy; 86 (62.7%) during the final two months; 41 (29.9%) during the final month. During the final month, 53 patients (38.7%) visited an emergency room more than once; 21 (15.3%) were admitted to the intensive care unit. Hospice referral occurred in 54% (74 patients) of the patients; 93.4% (128 patients) gave written do-not-resuscitate orders. Platelets, aspartate aminotransferase and creatinine changed significantly two weeks before death; total bilirubin, one month before; and C-reactive protein, between four and two weeks before death.
CONCLUSION
Our results demonstrated that a significant proportion of gastric cancer patients received palliative chemotherapy to the end of life and the patients who stopped the chemotherapy at least one month before death had a lower rate of intensive care unit admission and longer overall survival than those who sustained aggressive chemotherapy until the last months of their lives.

Citations

Citations to this article as recorded by

Decreased aggressive care at the end of life among advanced cancer patients in the Republic of Korea: a nationwide study from 2012 to 2018
Sara Kwon, Kyuwoong Kim, Bohyun Park, So-Jung Park, Hyun Jung Jho, Jin Young Choi
BMC Palliative Care.2024;[Epub] CrossRef
Automated machine learning (AutoML) can predict 90-day mortality after gastrectomy for cancer
Gopika SenthilKumar, Sharadhi Madhusudhana, Madelyn Flitcroft, Salma Sheriff, Samih Thalji, Jennifer Merrill, Callisia N. Clarke, Ugwuji N. Maduekwe, Susan Tsai, Kathleen K. Christians, T. Clark Gamblin, Anai N. Kothari
Scientific Reports.2023;[Epub] CrossRef
A prospective cohort study assessing aggressive interventions at the end-of-life among patients with solid metastatic cancer
Chetna Malhotra, Filipinas Bundoc, Isha Chaudhry, Irene Teo, Semra Ozdemir, Eric Finkelstein, Rebecca A. Dent, Nesaretnam Barr Kumarakulasinghe, Yin Bun Cheung, Rahul Malhotra, Ravindran Kanesvaran, Alethea Chung Pheng Yee, Noreen Chan, Huei Yaw Wu, Soh M
BMC Palliative Care.2022;[Epub] CrossRef
Quality of End-of-Life Care in Gastrointestinal Cancers: A 13-Year Population-Based Retrospective Analysis in Ontario, Canada
Caitlin SR Lees, Hsien Seow, Kelvin KW Chan, Anastasia Gayowsky, Aynharan Sinnarajah
Current Oncology.2022; 29(12): 9163. CrossRef
Use of Palliative Chemotherapy and ICU Admissions in Gastric and Esophageal Cancer Patients in the Last Phase of Life: A Nationwide Observational Study
Joost Besseling, Jan Reitsma, Judith A. Van Erkelens, Maike H. J. Schepens, Michiel P. C. Siroen, Cathelijne M. P. Ziedses des Plantes, Mark I. van Berge Henegouwen, Laurens V. Beerepoot, Theo Van Voorthuizen, Lia Van Zuylen, Rob H. A. Verhoeven, Hanneke
Cancers.2021; 13(1): 145. CrossRef
Efficacy of systemic oncological treatments in patients with advanced esophageal or gastric cancers at high risk of dying in the middle and short term: an overview of systematic reviews
M. Santero, J. Pérez-Bracchiglione, R. Acosta-Dighero, A. G. Meade, A. Antequera, A. Auladell-Rispau, M. J. Quintana, C. Requeijo, G. Rodríguez-Grijalva, K. Salas-Gama, R. Dorantes-Romandia, J. Salazar, I. Solà, G. Urrútia, X. Bonfill Cosp
BMC Cancer.2021;[Epub] CrossRef
Health care utilization at end of life among patients with lung or pancreatic cancer. Comparison between two Swedish cohorts
Helena Ullgren, Per Fransson, Anna Olofsson, Ralf Segersvärd, Lena Sharp, Amir Radfar
PLOS ONE.2021; 16(7): e0254673. CrossRef
Health care utilization among patients with oesophageal and gastric cancer: the impact of initial treatment strategy and assignment of a contact nurse
Karin Dalhammar, Marlene Malmström, Magnus Sandberg, Dan Falkenback, Jimmie Kristensson
BMC Health Services Research.2021;[Epub] CrossRef
Conceptualizing and Counting Discretionary Utilization in the Final 100 Days of Life: A Scoping Review
Paul R. Duberstein, Michael Chen, Michael Hoerger, Ronald M. Epstein, Laura M. Perry, Sule Yilmaz, Fahad Saeed, Supriya G. Mohile, Sally A. Norton
Journal of Pain and Symptom Management.2020; 59(4): 894. CrossRef
The impact of initial treatment strategy and survival time on quality of end-of-life care among patients with oesophageal and gastric cancer: A population-based cohort study
Karin Dalhammar, Marlene Malmström, Maria Schelin, Dan Falkenback, Jimmie Kristensson, Jason Chia-Hsun Hsieh
PLOS ONE.2020; 15(6): e0235045. CrossRef
Outpatient Palliative Care and Aggressiveness of End-of-Life Care in Patients with Metastatic Colorectal Cancer
Si Won Lee, Hyun Jung Jho, Ji Yeon Baek, Eun Kyung Shim, Hyun Mi Kim, Ji Yeon Ku, Eun Jung Nam, Yoon-Jung Chang, Hye Jin Choi, Sun Young Kim
American Journal of Hospice and Palliative Medicine®.2018; 35(1): 166. CrossRef
Patterns and Yearly Time Trends in the Use of Radiation Therapy During the Last 30 Days of Life Among Patients With Metastatic Rectal Cancer in the United States From 2004 to 2012
Adan Z. Becerra, Christian P. Probst, Fergal J. Fleming, Zhaomin Xu, Christopher T. Aquina, Carla F. Justiniano, Courtney I. Boodry, Alex A. Swanger, Katia Noyes, Alan W. Katz, John R. Monson, Todd A. Jusko
American Journal of Hospice and Palliative Medicine®.2018; 35(2): 336. CrossRef
Decreasing mortality and hospitalizations with rising costs related to gastric cancer in the USA: an epidemiological perspective
Delong Liu, Dhruv Mehta, Supreet Kaur, Arun Kumar, Kaushal Parikh, Lavneet Chawla, Shanti Patel, Amirta Devi, Aparna Saha
Journal of Hematology & Oncology.2018;[Epub] CrossRef
Frequency and Predictors of Acute Hospitalization Before Death in Patients With Glioblastoma
Eli L. Diamond, Katherine S. Panageas, Alexis Dallara, Ariel Pollock, Allison J. Applebaum, Alan C. Carver, Elena Pentsova, Lisa M. DeAngelis, Holly G. Prigerson
Journal of Pain and Symptom Management.2017; 53(2): 257. CrossRef
The effects of hospice-shared care for gastric cancer patients
Kun-Siang Huang, Shih-Ho Wang, Seng-Kee Chuah, Kun-Ming Rau, Yu-Hung Lin, Meng-Che Hsieh, Li-Hsueh Shih, Yen-Hao Chen, Ramon Andrade de Mello
PLOS ONE.2017; 12(2): e0171365. CrossRef
Clinical significance and predicting indicators of post‐cancer‐treatment survival in terminally ill patients with ovarian cancer
Fumi Utsumi, Hiroaki Kajiyama, Kaoru Niimi, Ryuichiro Sekiya, Jun Sakata, Shiro Suzuki, Kiyosumi Shibata, Mika Mizuno, Fumitaka Kikkawa
Journal of Obstetrics and Gynaecology Research.2017; 43(2): 365. CrossRef
Adopting Advance Directives Reinforces Patient Participation in End-of-Life Care Discussion
Ji Hyung Hong, Jung Hye Kwon, Il Kyu Kim, Jin Hee Ko, Yi-Jin Kang, Hoon-Kyo Kim
Cancer Research and Treatment.2016; 48(2): 753. CrossRef
Cases and Literature Review of Timing for Withdrawal of Palliative Chemotherapy
Yun Jin Jeong, Do Yeun Kim
The Korean Journal of Hospice and Palliative Care.2016; 19(1): 70. CrossRef
End-of-life care for hospitalized patients with metastatic melanoma in France: a nationwide, register-based study
I. Gallais Sérézal, Y. Beaussant, P. Rochigneux, C. Tournigand, R. Aubry, B. Lindelöf, L. Morin
British Journal of Dermatology.2016; 175(3): 583. CrossRef
Trends in the Aggressiveness of End-of-Life Cancer Care in the State of Qatar
Azza A. Hassan, Hassan Mohsen, Ayman A. Allam, Pascale Haddad
Journal of Global Oncology.2016; 2(2): 68. CrossRef
Investigational tests and treatments performed in terminal stage cancer patients in two weeks before death: Turkish oncology group (TOG) study
İbrahim Türker, Şeref Kömürcü, Ali Arıcan, Hatice Doruk, Özgür Özyılkan, Hasan Şenol Coşkun, Dilşen Çolak, Emel Üçgül Çavuşoğlu, Alper Ata, Ahmet Sezer, Havva Yeşil Çınkır, Filiz Çay Şenler, Fikret Arpacı
Medical Oncology.2014;[Epub] CrossRef

11,814 View
81 Download
21 Crossref

Modified FOLFIRI as Second-Line Chemotherapy after Failure of Modified FOLFOX-4 in Advanced Gastric Cancer: Eun Kyoung Jeon, Sook Hee Hong, Tae Hee Kim, Seung Eun Jung, Ji Chan Park, Hye-Sung Won, Yoon-Ho Ko, Sang Young Rho, Young Seon Hong; Cancer Res Treat. 2011;43(3):148-153. Published online September 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.3.148

Abstract PDF PubReader ePub

PURPOSE
The purpose of this study was to evaluate efficacy and toxicity of irinotecan, leucovorin and 5-fluorouracil (FOLFIRI) as second-line treatment after failure of oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) for advanced gastric cancer.
MATERIALS AND METHODS
Patients who received modified FOLFOX-4 as first-line treatment and then received sequential modified FOLFIRI for disease progression were included in this study. The modified FOLFIRI regimen consisted of irinotecan 150 mg/m2 in a 90-minute intravenous infusion on day 1, leucovorin (LV) 20 mg/m2 and 5-fluorouracil (5-FU) 400 mg/m2 as a bolus followed by 600 mg/m2 as a 22-hour infusion on days 1 and 2 with the same dose of 5-FU/LV of modified FOLFOX-4 every 2 weeks.
RESULTS
A total of 32 patients received 126 courses of FOLFIRI chemotherapy. No complete response was achieved. Three patients (9.4%; 95% confidence interval [CI], 0 to 20.1%) achieved partial response, whereas 11 (34.4%; 95% CI, 17.0 to 51.8%) patients showed stable disease. Disease control rate (complete response, partial responses and stable diseases) was 43.8% (95% CI, 25.6 to 61.9%) and median follow up duration was 11.3 months (range, 2.23 to 37.9 months). Median time to progression was 2 months (95% CI, 1.49 to 2.51 months), and median overall survival from the start of FOLFIRI was 5.84 months (95% CI, 4.34 to 7.34 months). Toxicities were tolerable.
CONCLUSION
Modified FOLFIRI as second-line chemotherapy after failure of the modified FOLFOX-4 in advanced gastric cancer was tolerable but showed a lower response rate. Further study about retrying 5-FU/LV with irinotecan after failure of the 5-FU/LV combined regimen is necessary in advanced gastric cancer.

Citations

Citations to this article as recorded by

Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Prognostic Nomogram and Patterns of Use of FOLFIRI-Aflibercept in Advanced Colorectal Cancer: A Real-World Data Analysis
Ana Fernández Montes, Carlos López López, Guillem Argilés Martínez, David Páez López, Ana María López Muñoz, Beatriz García Paredes, David Gutiérrez Abad, Carmen Castañón López, Paula Jiménez Fonseca, Javier Gallego Plazas, María Carmen López Doldán, Eva
The Oncologist.2019; 24(8): e687. CrossRef
Thymineless Death by the Fluoropyrimidine Polymer F10 Involves Replication Fork Collapse and Is Enhanced by Chk1 Inhibition
Chinnadurai Mani, Sachin Pai, Cinta Maria Papke, Komaraiah Palle, William H. Gmeiner
Neoplasia.2018; 20(12): 1236. CrossRef
Effect of FOLFOX4 combined with Brucea javanica emulsion on VEGF in patients with gastric cancer
Zheng Chen, Zhenyu Zhou, Zhigang Hu, Qiaodong Xu, Jie Wang
Oncology Letters.2017;[Epub] CrossRef
Sunitinib added to FOLFIRI versus FOLFIRI in patients with chemorefractory advanced adenocarcinoma of the stomach or lower esophagus: a randomized, placebo-controlled phase II AIO trial with serum biomarker program
Markus Moehler, Irina Gepfner-Tuma, Annett Maderer, Peter C. Thuss-Patience, Joern Ruessel, Susanna Hegewisch-Becker, Hansjochen Wilke, Salah-Eddin Al-Batran, Mohammad-Reza Rafiyan, Florian Weißinger, Hans-Joachim Schmoll, Frank Kullmann, Ludwig Fischer v
BMC Cancer.2016;[Epub] CrossRef
5-Fluorouracil derivatives: a patent review (2012 – 2014)
Esmeralda Carrillo, Saúl Abenhamar Navarro, Alberto Ramírez, María Ángel García, Carmen Griñán-Lisón, Macarena Perán, Juan Antonio Marchal
Expert Opinion on Therapeutic Patents.2015; 25(10): 1131. CrossRef
Efficacy and Safety of FOLFIRI as Second-line Chemotherapy in Advanced Gastric Cancer
Sung Chul Park, Hoon Jai Chun
The Korean Journal of Gastroenterology.2015; 66(1): 1. CrossRef
Efficacy and Safety of FOLFIRI after Failure of FOLFOX-4 in Advanced Gastric Cancer
Hye Jung Kwon, Moo In Park, Seun Ja Park, Won Moon, Sung Eun Kim, Hae Won Lee, Youn Jung Choi, Jae Hyun Kim
The Korean Journal of Gastroenterology.2015; 66(1): 10. CrossRef
FOLFIRI as Second-line Chemotherapy after Failure of FOLFOX4 in Advanced Colorectal Cancer: A Korean Single-center Experience
Jae Hyun Kim, Seun Ja Park, Moo In Park, Won Moon, Sung Eun Kim, Ki Hwan Ku, Sung Eun Song, Je Hun Kim
The Korean Journal of Gastroenterology.2014; 63(1): 18. CrossRef
5-Fluorouracil derivatives: a patent review
Pablo Álvarez, Juan Antonio Marchal, Houria Boulaiz, Esmeralda Carrillo, Celia Vélez, Fernando Rodríguez-Serrano, Consolación Melguizo, Jose Prados, Roberto Madeddu, Antonia Aranega
Expert Opinion on Therapeutic Patents.2012; 22(2): 107. CrossRef
Outcomes of Third-Line Docetaxel-Based Chemotherapy in Advanced Gastric Cancer Who Failed Previous Oxaliplatin-Based and Irinotecan-Based Chemotherapies
Min Jeong Lee, In Gyu Hwang, Joung-Soon Jang, Jin Hwa Choi, Byeong-Bae Park, Myung Hee Chang, Seung Tae Kim, Se Hoon Park, Myoung Hee Kang, Jung Hun Kang
Cancer Research and Treatment.2012; 44(4): 235. CrossRef
Irinotecan, leucovorin and 5-fluorouracil (modified FOLFIRI) as salvage chemotherapy for frail or elderly patients with advanced gastric cancer
JUNG HAN KIM, HYEONG SU KIM, A RUM HAN, IN HO MOH, DOO CHEOL CHUNG, DAE RO CHOI, HYUN JOO JANG, JIN BAE KIM, DAE HYUN YANG, SOON IL LEE, DAE YOUNG ZANG
Oncology Letters.2012; 4(4): 751. CrossRef

11,550 View
83 Download
12 Crossref

Case Report

Numb Chin Syndrome with Concomitant Painful Ophthalmoplegia Leading to a Diagnosis of Diffuse Large B Cell Lymphoma: Yeong-Il Kim, Jae-Young An, Kwang-Soo Lee, Hye Young Sung, Young Seon Hong, Won Kyung Kang, Chan-Kwon Jung, Joong-Seok Kim; Cancer Res Treat. 2011;43(2):134-138. Published online June 30, 2011; DOI: https://doi.org/10.4143/crt.2011.43.2.134

Abstract PDF PubReader ePub

Painful ophthalmoplegia (PO) and concomitant numb chin syndrome (NCS) is a very rare event. There are a few reports in the literature about PO and concomitant NCS that have preceded the diagnosis of a malignancy. In this report, we describe a patient with diffuse large B cell lymphoma who presented with PO and concomitant NCS as the initial symptom of the disease.

Citations

Citations to this article as recorded by

Numb chin syndrome
Cristina Perez, Reny de Leeuw, Francisco Escala P., Rodrigo Fuentealba, Gary D. Klasser
The Journal of the American Dental Association.2023; 154(1): 79. CrossRef
Numb chin syndrome in sickle cell disease: a case series of Jamaican patients
Zachary Ramsay, Christine Hammond Gabbadon, Monika Asnani
Annals of Hematology.2021; 100(4): 913. CrossRef
A case of paresthesia of the contralateral mental region suspected to be an early symptom of diffuse large B-cell lymphoma
Daiki TAKAHASHI, Masaya AKASHI, Yusuke TAKAHASHI, Kazuyuki TSUJI, Tsutomu MINAMIKAWA, Takahide KOMORI
Japanese Journal of Oral and Maxillofacial Surgery.2016; 62(4): 163. CrossRef
Síndrome del mentón entumecido como manifestación de recidiva tumoral
M. García-Lamazares, O. Ferreiro-Uriz, L. Alfaya-García
SEMERGEN - Medicina de Familia.2014; 40(2): e43. CrossRef
Primary Retroperitoneal Diffuse Large B-cell Lymphoma Presenting with Numb Chin Syndrome and Painful Ophthalmoplegia
Satoshi Ichikawa, Kei Saito, Takuma Suzuki, Jun Kimura, Hideo Harigae
Internal Medicine.2013; 52(16): 1813. CrossRef

11,659 View
64 Download
5 Crossref

Original Articles

Clinical Significance of Vascular Endothelial Growth Factors (VEGF)-C and -D in Resected Non-Small Cell Lung Cancer: Yoon Ho Ko, Chan-Kwon Jung, Myung-Ah Lee, Jae Ho Byun, Jin Hyoung Kang, Kyo Young Lee, Keon Hyun Jo, Young Pil Wang, Young Seon Hong; Cancer Res Treat. 2008;40(3):133-140. Published online September 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.3.133

Abstract PDF PubReader ePub

Purpose

Lymphatic spread of tumor is an important prognostic factor for patients with non-small cell lung carcinoma (NSCLC). Vascular endothelial growth factor-C (VEGF-C) and VEGF-D play important roles in lymphangiogenesis via the VEGF receptor 3 (VEGFR-3). We sought to determine whether VEGF-C, VEGF-D and VEGFR-3 are involved in the clinical outcomes of patients with resected NSCLC.

Materials and Methods

Using immunohistochemical staining, we investigated the protein expressions of VEGF-C, VEGF-D and VEGFR-3 in the tissue array specimens from patients who underwent resection for NSCLC. The immunoreactivity for p53 was also examined. The clinicopathological implications of these molecules were statistically analyzed.

Results

Analysis of a total of 118 specimens showed that VEGF-C, VEGF-D and their co-expression were significantly associated with more advanced regional lymph node metastasis (p=0.019, p=0.044 and p=0.026, respectively, N2 versus N0 and N1). A VEGFR-3 expression had a strong correlation with peritumoral lymphatic invasion (p=0.047). On the multivariate analysis for survival and recurrence, pathologic N2 lymph node metastasis was the only independent prognostic factor, but none of the investigated molecules showed any statistical correlation with recurrence and survival.

Conclusions

The present study revealed that high expressions of VEGF-C and VEGF-D were strongly associated with more advanced regional lymph node metastasis in patients with resected NSCLC.

Citations

Citations to this article as recorded by

Advances in lymphatic metastasis of non-small cell lung cancer
Xiaofei Zhang, Li Ma, Man Xue, Yanning Sun, Zhaoxia Wang
Cell Communication and Signaling.2024;[Epub] CrossRef
Prediction of VEGF and EGFR Expression in Peripheral Lung Cancer Based on the Radiomics Model of Spectral CT Enhanced Images
Linhua Wu, Jian Li, Xiaowei Ruan, Jialiang Ren, Xuejun Ping, Bing Chen
International Journal of General Medicine.2022; Volume 15: 6725. CrossRef
Lymphangiogenesis in Gastric Cancer regulated through Akt/mTOR-VEGF-C/VEGF-D axis
Hongxia Chen, Runnian Guan, Yupeng Lei, Jianyong Chen, Qi Ge, Xiaoshen Zhang, Ruoxu Dou, Hongyuan Chen, Hao Liu, Xiaolong Qi, Xiaodong Zhou, Changyan Chen
BMC Cancer.2015;[Epub] CrossRef
Prognostic Impact of Elevation of Vascular Endothelial Growth Factor Family Expression in Patients with Non-small Cell lung Cancer: an Updated Meta-analysis
Chun-Long Zheng, Chen Qiu, Mei-Xiao Shen, Xiao Qu, Tie-Hong Zhang, Ji-Hong Zhang, Jia-Jun Du
Asian Pacific Journal of Cancer Prevention.2015; 16(5): 1881. CrossRef
Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer - A Structured Review with Meta-Analysis
Thomas K. Kilvaer, Erna-Elise Paulsen, Sigurd M. Hald, Tom Wilsgaard, Roy M. Bremnes, Lill-Tove Busund, Tom Donnem, Xin-Yuan Guan
PLOS ONE.2015; 10(8): e0132481. CrossRef
A Gene Signature Combining the Tissue Expression of Three Angiogenic Factors is a Prognostic Marker in Early-stage Non-small Cell Lung Cancer
Elena Sanmartín, Rafael Sirera, Marta Usó, Ana Blasco, Sandra Gallach, Santiago Figueroa, Nieves Martínez, Cristina Hernando, Antonio Honguero, Miguel Martorell, Ricardo Guijarro, Rafael Rosell, Eloisa Jantus-Lewintre, Carlos Camps
Annals of Surgical Oncology.2014; 21(2): 612. CrossRef
VEGF-C in non-small cell lung cancer: Meta-analysis
Hao Jiang, Wei Shao, Wei Zhao
Clinica Chimica Acta.2014; 427: 94. CrossRef
High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend?
Julia Rudno-Rudzinska, Wojciech Kielan, Zygmunt Grzebieniak, Piotr Dziegiel, Piotr Donizy, Grzegorz Mazur, Monika Knakiewicz, Ewelina Frejlich, Agnieszka Halon
Gastric Cancer.2013; 16(4): 513. CrossRef
Multiplexed analysis of angiogenesis and lymphangiogenesis factors predicts outcome for non-small cell lung cancer patients
Valsamo K. Anagnostou, Dina G. Tiniakos, Marianthi Fotinou, Apostolos Achimastos, Konstantinos N. Syrigos
Virchows Archiv.2011; 458(3): 331. CrossRef
Prognostic significance of epidermal growth factor receptor and vascular endothelial growth factor receptor in colorectal adenocarcinoma
JUNG YEON KIM, BYUNG-NOE BAE, JI EUN KWON, HYUN-JUNG KIM, KYEONGMEE PARK
APMIS.2011; 119(7): 449. CrossRef
Supplementation with a-Tocopherol or ß-Carotene Reduces Serum Concentrations of Vascular Endothelial Growth Factor-D, but Not -A or -C, in Male Smokers
Alison M. Mondul, Helen C. Rager, William Kopp, Jarmo Virtamo, Demetrius Albanes
The Journal of Nutrition.2011; 141(11): 2030. CrossRef
Expression Analysis of Angiogenesis-Related Genes in Bulgarian Patients with Early-Stage Non-Small Cell Lung Cancer
Svetlana Nikolova Metodieva, Dragomira Nikolaeva Nikolova, Radostina Vlaeva Cherneva, Ivanka Istalianova Dimova, Danail Borisov Petrov, Draga Ivanova Toncheva
Tumori Journal.2011; 97(1): 86. CrossRef

9,822 View
47 Download
12 Crossref

Discrepant Views of Korean Medical Oncologists and Cancer Patients on Complementary and Alternative Medicine: Do Yeun Kim, Bong-Seog Kim, Kyung Hee Lee, Myung Ah Lee, Young Seon Hong, Sang Won Shin, Soon Nam Lee; Cancer Res Treat. 2008;40(2):87-92. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.87

Abstract PDF PubReader ePub

Purpose

This study was designed to evaluate the communication gap between Korean medical oncologists and cancer patients on complementary and alternative medicine (CAM).

Materials and Methods

Cross sectional studies utilized the responses of 59 medical oncologists and 211 patients. To understand the communication gap, perceived reasons and nondisclosure of CAM use, reactions of physicians to disclosure, and expectations for CAM were analyzed. Data were compared with use of the chi-squared test.

Results

Both medical oncologists and patients were in accord that CAM use would privde the patients with a feeling of hope. The medical oncologists believed more often than patients to attribute CAM use for control over medical care decisions, for the treatment of an incurable disease or as a nontoxic approach (p<0.05). Regarding reasons for nondisclosure, medical oncologists were more likely to think that physicians would not understand the use of CAM, discontinue treatment or disapprove of the use of CAM (p<0.0001). Patients attributed nondisclosure mainly to the lack of questioning about CAM. Medical oncologists were more likely to warn of the risks with CAM use and less likely to encourage the use of CAM than perceived by patients (p=0.01). Patients expected that CAM could cure disease, extend survival, relieve symptoms and improve the immune system or quality of life more often than medical oncologists (p<0.05).

Conclusion

Given the discrepant views of medical oncologists and patients on the use of CAM, medical oncologists should be aware of the discrepancies and attempt to resolve any differences.

Citations

Citations to this article as recorded by

Use of decision aid to improve informed decision-making and communication with physicians on the use of oral complementary and alternative medicine (CAM) among cancer patients on chemotherapy treatment: a randomised controlled trial
Wan-Qin Chong, Maria Jannet Mogro, Asrie Arsad, Bee-Choo Tai, Soo-Chin Lee
Supportive Care in Cancer.2021; 29(7): 3689. CrossRef
Discrepant Views of Oncologists and Cancer Patients on Complementary and Alternative Medicine in a Chinese General Hospital
Geliang Yang, Huiqing Zhang, Zheng Gan, Yifu Fan, Wei Gu, Changquan Ling
Integrative Cancer Therapies.2018; 17(2): 451. CrossRef
Information and Training Needs Regarding Complementary and Alternative Medicine: A Cross-sectional Study of Cancer Care Providers in Germany
Gudrun E. Klein, Corina Guethlin
Integrative Cancer Therapies.2018; 17(2): 380. CrossRef
China’s cancer patients’ perceptions, attitudes and participation in clinical trials of complementary and alternative medicine: A multi-center cross-sectional study
Yifu Fan, Huiqing Zhang, Geliang Yang, Cheng Wu, Yuyu Guo, Changquan Ling
European Journal of Integrative Medicine.2018; 19: 115. CrossRef
National survey of China's oncologists' knowledge, attitudes, and clinical practice patterns on complementary and alternative medicine
Geliang Yang, Richard Lee, Huiqing Zhang, Wei Gu, Peiying Yang, Changquan Ling
Oncotarget.2017; 8(8): 13440. CrossRef
Expected and perceived efficacy of complementary and alternative medicine: A comparison views of patients with cancer and oncologists
Sang Hyuck Kim, Dong Wook Shin, You-Seon Nam, So Young Kim, Hyung-kook Yang, Be Long Cho, Keeho Park, Heui-Sug Jo, Chang-Yeol Yim, Sin Kam, Jong-Hyock Park
Complementary Therapies in Medicine.2016; 28: 29. CrossRef
Survey of Policies and Guidelines on Antioxidant Use for Cancer Prevention, Treatment, and Survivorship in North American Cancer Centers
Gyeongyeon Hong, Jennifer White, Lihong Zhong, Linda E. Carlson
Integrative Cancer Therapies.2015; 14(4): 305. CrossRef
National Survey of US Oncologists' Knowledge, Attitudes, and Practice Patterns Regarding Herb and Supplement Use by Patients With Cancer
Richard T. Lee, Andrea Barbo, Gabriel Lopez, Amal Melhem-Bertrandt, Heather Lin, Olufunmilayo I. Olopade, Farr A. Curlin
Journal of Clinical Oncology.2014; 32(36): 4095. CrossRef
Perception and attitude of Jordanian physicians towards complementary and alternative medicine (CAM) use in oncology
Amal Al-Omari, Mohammad Al-Qudimat, Amid Abu Hmaidan, Luna Zaru
Complementary Therapies in Clinical Practice.2013; 19(2): 70. CrossRef
Investigation into the Use of Complementary and Alternative Medicine and Factors Affecting Use in Korean Patients with Brain Tumors
Yong Soon Shin, Jeong A Lee, So Hyun Bae, Su Youn Lee, Min Kyeong Jang
Journal of Korean Academy of Fundamentals of Nursing.2013; 20(2): 147. CrossRef
Complementary and alternative medicine use and assessment of quality of life in Korean breast cancer patients: a descriptive study
Eunyoung Kang, Eun Joo Yang, Sun-Mi Kim, Il Yong Chung, Sang Ah Han, Do-Hoon Ku, Soek-Jin Nam, Jung-Hyun Yang, Sung-Won Kim
Supportive Care in Cancer.2012; 20(3): 461. CrossRef
Validation of the Korean Integrative Medicine Attitude Questionnaire (IMAQ)
Jung-Ha Kim, Jung-Bok Lee, Duk-Chul Lee
Korean Journal of Family Medicine.2011; 32(3): 197. CrossRef

9,424 View
54 Download
12 Crossref

Treatment Outcome of Cisplatin-based Concurrent Chemoradiotherapy in the Patients with Locally Advanced Nasopharyngeal Cancer: Tae Hee Kim, Yoon Ho Ko, Myung Ah Lee, Bum-soo Kim, So Ryoung Chung, Ie Ryung Yoo, Chan-Kwon Jung, Yeon-Sil Kim, Min Sik Kim, Dong-Il Sun, Young Seon Hong, Kyung Shik Lee, Jin-Hyoung Kang; Cancer Res Treat. 2008;40(2):62-70. Published online June 30, 2008; DOI: https://doi.org/10.4143/crt.2008.40.2.62

Abstract PDF PubReader ePub

Purpose

The standard treatment of locally advanced nasopharyngeal cancer is a concurrent chemoradiotherapy (CCRT), and cisplatin has been used as the most popular chemotherapeutic agent. But many different doses and schedules for cisplatin administration such as daily, weekly and 3 week cycles have been proposed. We compared and analyzed the tumor response, the overall survival, the toxicity and the chemotherapy dose intensity in the patients with locally advanced nasopharyngeal cancer who were treated with CCRT.

Materials and Methods

We performed a retrospective study on 55 patients with locally advanced nasopharyngeal cancer, and they were treated with CCRT as a front-line treatment from Jan 1996 to Jun 2007 at Kangnam Saint Mary's Hospital.

Results

The patients had a median age of 53 years (range: 19~75 years). Of the total 55 patients, a 3-week cycle of 100mg cisplatin was administered in 31 patients and 30 mg weekly cisplatin was administered in 24 patients combined with radiotherapy. Twenty one patients had a complete response and four patients had a partial response for a response rate of 71.4% (95% CI: 59.5~83.3) after CCRT and followed by adjuvant chemotherapy. The complete response rates for the 30 mg and 100 mg cisplatin groups were 72.7% (95% CI: 54.9~90.5) and 54.2% (95% CI: 36.7~71.7), respectively (p=0.23). The duration of CCRT in the 100mg cisplatin group was significantly longer than that of the 30mg cisplatin group (11.1±2.9 weeks vs. 9.0±1.2 weeks, p=0.003). The major deviation group, which was defined as prolongation of the radiotherapy duration for more than 2 weeks, had a significantly lower objective response rate than did the non-deviation group (56.3% vs 84.2%, respectively, p=0.002). The major severe toxicities were leucopenia (49.1%), pharyngoesophagitis (49.1%), anorexia (43.6%), nausea (41.8%) and vomiting (40%).

Conclusions

Weekly 30mg cisplatin-based CCRT is a practical, feasible cisplatin schedule for the patients with locally advanced nasopharyngeal cancer in regard to decreasing the interruption of radiation treatment and decreasing the treatment-related acute toxicities.

Citations

Citations to this article as recorded by

A prognostic and predictive model based on deep learning to identify optimal candidates for intensity-modulated radiotherapy alone in patients with stage II nasopharyngeal carcinoma: A retrospective multicenter study
Jiong-Lin Liang, Yue-Feng Wen, Ying-Ping Huang, Jia Guo, Yun He, Hong-Wei Xing, Ling Guo, Hai-Qiang Mai, Qi Yang
Radiotherapy and Oncology.2025; 203: 110660. CrossRef
The Effect of Prolonged Duration of Intensity Modulated Radiotherapy for Nasopharyngeal Carcinoma
Yi-Jun Hua, Yan-Feng Ou-Yang, Xiong Zou, Le Xia, Dong-Hua Luo, Ming-Yuan Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Taxane-based Induction Chemotherapy Plus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: Prospective Results from a Non-endemic Cohort
S. Ghosh-Laskar, A. Pilar, K. Prabhash, A. Joshi, J.P. Agarwal, T. Gupta, A. Budrukkar, V. Murthy, M. Swain, V. Noronha, V.M. Patil, P. Pai, D. Nair, D.A. Chaukar, S. Thiagarajan, G. Pantvaidya, A. Deshmukh, P. Chaturvedi, S. Nair, A. D‘Cruz
Clinical Oncology.2019; 31(12): 850. CrossRef
Long-term outcomes of concurrent chemoradiotherapy versus radiotherapy alone in stage II nasopharyngeal carcinoma treated with IMRT: a retrospective study
Zhen Su, Yan-Ping Mao, Jie Tang, Xiao-Wen Lan, Pu-Yun OuYang, Fang-Yun Xie
Tumor Biology.2016; 37(4): 4429. CrossRef
Concurrent chemoradiotherapy was associated with a higher severe late toxicity rate in nasopharyngeal carcinoma patients compared with radiotherapy alone: a meta-analysis based on randomized controlled trials
Cheng-run Du, Hong-mei Ying, Fang-fang Kong, Rui-ping Zhai, Chao-su Hu
Radiation Oncology.2015;[Epub] CrossRef
Concurrent Chemotherapy for T4 Classification Nasopharyngeal Carcinoma in the Era of Intensity-Modulated Radiotherapy
Cai-neng Cao, Jing-wei Luo, Li Gao, Jun-lin Yi, Xiao-dong Huang, Kai Wang, Shi-ping Zhang, Yuan Qu, Su-yan Li, Jian-ping Xiao, Zhong Zhang, Guo-zhen Xu, Riccardo Dolcetti
PLOS ONE.2015; 10(3): e0119101. CrossRef
Controversies in the systemic treatment of Nasopharyngeal carcinoma
Herbert H. Loong, Anthony T.C. Chan
Oral Oncology.2014; 50(9): 785. CrossRef
Intensity-modulated radiotherapy with simultaneous integrated boost for locoregionally advanced nasopharyngeal carcinoma
Junlin Yi, Xiaodong Huang, Li Gao, Jingwei Luo, Shiping Zhang, Kai Wang, Yuan Qu, Jianping Xiao, Guozhen Xu
Radiation Oncology.2014;[Epub] CrossRef
Factors Predict Prolonged Wait Time and Longer Duration of Radiotherapy in Patients with Nasopharyngeal Carcinoma: A Multilevel Analysis
Po-Chun Chen, Ching-Chieh Yang, Cheng-Jung Wu, Wen-Shan Liu, Wei-Lun Huang, Ching-Chih Lee, Bart O. Williams
PLoS ONE.2014; 9(10): e109930. CrossRef
Pretreatment Epstein-Barr Virus DNA Load and Cumulative Cisplatin Dose Intensity Affect Long-Term Outcome of Nasopharyngeal Carcinoma Treated with Concurrent Chemotherapy: Experience of an Institute in an Endemic Area
Weihong Wei, Zeli Huang, Shaoen Li, Hemei Chen, Guoyi Zhang, Shuxia Li, Weihan Hu, Tao Xu
Oncology Research and Treatment.2014; 37(3): 88. CrossRef
Concurrent Chemoradiotherapy vs Radiotherapy Alone in Stage II Nasopharyngeal Carcinoma: Phase III Randomized Trial
Qiu-Yan Chen, Yue-Feng Wen, Ling Guo, Huai Liu, Pei-Yu Huang, Hao-Yuan Mo, Ning-Wei Li, Yan-Qun Xiang, Dong-Hua Luo, Fang Qiu, Rui Sun, Man-Quan Deng, Ming-Yuan Chen, Yi-Jun Hua, Xiang Guo, Ka-Jia Cao, Ming-Huang Hong, Chao-Nan Qian, Hai-Qiang Mai
JNCI: Journal of the National Cancer Institute.2011; 103(23): 1761. CrossRef
Radiation Therapy Combined with (or without) Cisplatin-based Chemotherapy for Patients with Nasopharyngeal Cancer: 15-years Experience of a Single Institution in Korea
Yeon-Sil Kim, Bum-Soo Kim, So-Lyoung Jung, Yeon-Soo Lee, Min-Sik Kim, Dong-Il Sun, Eun-Jung Yoo, Seong-Kwon Mun, Sei-Chul Yoon, Su-Mi Chung, Hoon-Kyo Kim, Seung-Ho Jo, Jin-Hyoung Kang
Cancer Research and Treatment.2008; 40(4): 155. CrossRef

12,375 View
70 Download
12 Crossref

Clinical Characteristics of Primary Peritoneal Carcinoma: Sang Young Roh, Sook Hee Hong, Yoon Ho Ko, Tae Hee Kim, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, In Sook Woo, Jin Hyoung Kang, Young Seon Hong, Kyung Shik Lee; Cancer Res Treat. 2007;39(2):65-68. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.65

Abstract PDF PubReader ePub

Purpose

The goal of this study was to determine the clinical and therapeutic characteristics of women with a primary peritoneal carcinoma (PPC).

Materials and Methods

A retrospective clinical study was conducted to evaluate 22 women diagnosed with a PPC from 1993 to 2007 at the Hospitals of The Catholic University of Korea. Diagnoses were based on the Gynecologic Oncology Group criteria and clinical data. We collected patient clinicopathological data including age, presenting symptoms, pretreatment CA-125 values (U/ml), clinical stage (based on the FIGO stage), performance status (using the Eastern Cooperative Oncology Group scale), whether cytoreductive surgery was optimal or not, types of chemotherapy and response to treatment. We evaluated the clinical characteristics and response to treatment, time to treatment failure and overall survival.

Results

The median overall survival of all patients was 23.1 months. The estimated 3-year survival rate was 29% (SE, 13%). The response rate to first-line platinum-based chemotherapy was 79% and the median time to treatment failure was 9.9 months (95% confidence interval, 1.38~18.4 months). By univariate and multivariate analysis, performance status was the only significant factor associated with overall survival (p<0.05).

Conclusion

We evaluated the clinical characteristics and treatment response of patients with a primary peritoneal carcinoma. Our results showed that it is possible to achieve long-term survival in patients with PPC. A further clinical study is to need to establish clinical characteristics and treatment outcomes.

Citations

Citations to this article as recorded by

Incidentally Diagnosed Low-Grade Primary Peritoneal Serous Carcinoma Within the Umbilical Hernia Sac in a Male: A Report of an Extremely Rare Case and Review of the Literature
Samer Ganam, Ayesha Khan, Nicole Riddle, Joseph A Sujka, Christopher G DuCoin
Cureus.2024;[Epub] CrossRef
Primary peritoneal high-grade serous carcinoma in a man: A case report
Abdelali Guellil, Rachid Jabi, Mohamed Yassine Mabrouk, Laila Bouzayan, Abdelali Merhoum, Gérald Del Gallo, Claire Godart, Mohammed Bouziane
Annals of Medicine and Surgery.2022; 77: 103605. CrossRef
Primary Peritoneal Carcinoma: A Rare Malignancy Presenting a Diagnostic Challenge
Mariam Shabbir, Sonu Sahni, Meena Ahluwalia, Raji Ayinla
Cureus.2022;[Epub] CrossRef
A case of interstitial pneumonia associated with systemic sclerosis and primary peritoneal serous carcinoma successfully treated with cyclophosphamide
Shunichi Kawamura, Toshio Kubo, Kenji Takada, Ryota Sunami, Sachi Okawa, Yoshitaka Iwamoto, Atsuko Hirabae, Akihiko Taniguchi, Yoshinobu Maeda, Katsuyuki Kiura, Masahiro Tabata
International Cancer Conference Journal.2021; 10(3): 197. CrossRef
Primary peritoneal mucinous cystadenocarcinoma mimicking possible recurrent ovarian mucinous cystadenoma: coincidental pathology or a spectrum of disease?
Claire Filippini, Sarah Smyth, Hooman Soleymani Majd, Catherine Johnson
BMJ Case Reports.2021; 14(7): e242478. CrossRef
Imaging features of primary peritoneal serous carcinoma: A case report
Ji Soo Oh, Beum Jin Kim, Myoung Jin Ju, Eun Ae Yoo
Radiology Case Reports.2020; 15(7): 978. CrossRef
Unexpected primary fallopian tube carcinoma during gynecological operations: Clinicopathological and prognostic factors analyses of 67 cases
Mingming Sun, Lingjie Bao, Haoran Shen, Min Ji, Liangqing Yao, Xiaofang Yi, Wei Jiang
Taiwanese Journal of Obstetrics and Gynecology.2019; 58(5): 626. CrossRef
Complications of Acute Pancreatitis Misdiagnosed as Primary Serous Papillary Carcinoma
Jin Wook Lee, Eun Taek Park
The Korean Journal of Pancreas and Biliary Tract.2018; 23(2): 54. CrossRef
Inguinal Lymph Node Metastasis of a Primary Serous Papillary Carcinoma of the Peritoneum One Year after CRS and HIPEC
Shadi Katou, Mathilde Feist, Wieland Raue, Johann Pratschke, Beate Rau, Andreas Brandl
Visceral Medicine.2018; 34(4): 307. CrossRef
Diagnostic and prognostic value of HE4 in female patients with primary peritoneal carcinoma
Dong Mi, Yuexiang Zhang
The International Journal of Biological Markers.2018; 33(4): 395. CrossRef
Long-term survival of high-grade primary peritoneal papillary serous adenocarcinoma: a case report and literature review
Jingping Yuan, Liang He, Bing Han, Yan Li
World Journal of Surgical Oncology.2017;[Epub] CrossRef
An unusual cancer involving the rectum: two cases of localized primary peritoneal carcinoma mimicking rectal carcinoma
Jinnie S. Y. Pang, Liying Yang, Ghee Kheng Chew, Min Hoe Chew
International Journal of Colorectal Disease.2016; 31(3): 717. CrossRef
Primary peritoneal serous carcinoma, an extremely rare malignancy: A case report and review of the literature
WOO-SUNG YUN, JUNG-MIN BAE
Oncology Letters.2016; 11(6): 4063. CrossRef
Adenocarcinoma of Mullerian origin: review of pathogenesis, molecular biology, and emerging treatment paradigms
Lauren Patterson Cobb, Stephanie Gaillard, Yihong Wang, Ie-Ming Shih, Angeles Alvarez Secord
Gynecologic Oncology Research and Practice.2015;[Epub] CrossRef
Amylase-Producing Primary Peritoneal Carcinoma
Ji-Woon Lee, Sang-Gon Park
The Korean Journal of Medicine.2015; 89(3): 358. CrossRef
Solitary primary peritoneal carcinoma arising from the omentum
Yi-Jou Tai, Ming-Chieh Lin, Chin-Jui Wu, Chi-An Chen, Wen-Fang Cheng
Taiwanese Journal of Obstetrics and Gynecology.2014; 53(2): 256. CrossRef
Primary peritoneal clear cell carcinoma treated with IMRT and interstitial HDR brachytherapy: a case report
Skyler B. Johnson, Joann I. Prisciandaro, Jessica Zhou, Scott W. Hadley, R. Kevin Reynolds, Shruti Jolly
Journal of Applied Clinical Medical Physics.2014; 15(1): 202. CrossRef
Embryonic natural orifice transumbilical endoscopic surgery (E-NOTES) for adnexal tumors
Myong Cheol Lim, Tae-Joong Kim, Sokbom Kang, Duk-Soo Bae, Sang-Yoon Park, Sang-Soo Seo
Surgical Endoscopy.2009; 23(11): 2445. CrossRef

10,316 View
92 Download
18 Crossref

Autologous Stem Cell Transplantation using a Modified TAM Conditioning Regimen for Clinically Aggressive Non-Hodgkin's Lymphoma: Sook Hee Hong, Young Seon Hong, In Sook Woo, Yoon Ho Koh, Sang Young Rho, Ji Yean Peak, Myung Ah Lee, Byoung Yong Shim, Jae Ho Byun, Ji Chan Park, Jong Wook Lee, Woo Sung Min, Chun Choo Kim; Cancer Res Treat. 2007;39(2):54-60. Published online June 30, 2007; DOI: https://doi.org/10.4143/crt.2007.39.2.54

Abstract PDF PubReader ePub

Purpose

High-dose chemotherapy (HDT) and autologous stem cell transplantation (ASCT) have been used for the treatment of clinically aggressive non-Hodgkin's lymphoma (NHL). However, the superiority of specific conditioning regimens has not yet been established. The present study evaluated the efficacy and toxicity of a conditioning regimen involving fractionated total body irradiation (TBI), and the use of Ara-C and melphalan (TAM) for clinically aggressive NHL.

Materials and Methods

Between March 2002 and December 2004, 31 patients with aggressive NHL received fractionated TBI with a dose of 12 Gy over 3 days, and were administered 9 g/m² Ara-C and 100 mg/m² melphalan followed by autologous peripheral blood stem Cell Transplantation at the Catholic Hematopoietic Stem cell transplantation Center Korea. Patients that responded to first line chemotherapy and achieved complete remission (CR), or were in a first sensitive relapse were defined as having less advanced disease, while the other patients were defined as having more advanced disease.

Results

Objective responses were obtained in 24 of 31 patients (77.4%), comprising complete remission in 19 patients (61.3%) and partial remission in 5 (16.1%) patients. The median follow-up time was 28 months (range 1~62 months). At 3 years, the overall survival and event-free survival (EFS) rates were 62.3% and 47.3%, respectively. Patients with less advanced disease and more advanced disease showed 3-year EFS rates of 73.3% and 22.5 %, respectively (p=0.006). Early (within the first 100 days) treatment-related mortality occurred in 3 (9.7%) patients. Of the 31 total patients, 15 (48.4%) developed grade 3 mucositis, 22 (70.9%) developed neutropenic fever, and two (6.5%) developed interstitial pneumonia syndrome>grade 3.

Conclusion

The modified TAM conditioning regimen and ASCT appear to be a feasible treatment regimen for clinically aggressive NHL, particularly for patients with less advanced disease.

Citations

Citations to this article as recorded by

Comparison of regional arterial chemotherapy and systemic intravenous chemotherapy for advanced pancreatic cancer: a systematic review and meta-analysis
Chengqing Li, Wenyi Guo, Shihong Chen, Jianwei Xu, Feng Li, Lei Wang
Journal of Pancreatology.2022; 5(2): 49. CrossRef

9,659 View
55 Download
1 Crossref

Effect of Arsenic Trioxide in TRAIL (Tumor Necrosis Factor-related Apoptosis Inducing Ligand)-Mediated Apoptosis in Multiple Myeloma Cell Lines: Jae Ho Byun, Young Seon Hong, Hee Jeong Cheong, Sook Ja Kim, Nam Su Lee, Jong Ho Won, Dae Sik Hong, Hee Sook Park; Cancer Res Treat. 2003;35(6):472-477. Published online December 31, 2003; DOI: https://doi.org/10.4143/crt.2003.35.6.472

Abstract PDF: PURPOSE
The potential therapeutic application of the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), in the treatment of multiple myeloma (MM), was recently proposed. However, there have been some problems with the use of TRAIL, due to the appearance of TRAIL-resistant cells in MM. The effect of arsenic trioxide (As2O3) on the rate of apoptosis induced by TRAIL was evaluated in MM cells.
MATERIALS AND METHODS
Using TRAIL-sensitive (RPMI- 8226) and TRAIL-resistant (ARH-77 and IM-9) MM cell lines, the cell viability, induction of apoptosis, and change in the caspases were examined after treatment with TRAIL alone, or in combination with various concentrations of As2O3.
RESULTS
Incubating the cell lines with As2O3 augmented the TRAIL-induced apoptosis in the MM cell lines, according to the As2O3 concentration. Apoptosis was mediated through caspase activation. When TRAIL was used alone, caspase8 was activated in the RPMI-8226 cell lines, but not in the ARH-77 and IM-9 cell lines. When As2O3 was added to TRAIL, caspase-9 was activated in the ARH-77 and IM-9 cells.
CONCLUSION
The use of As2O3, in combination with TRAIL, would help enhance the level of TRAIL-induced apoptosis, and overcome the TRAIL-resistance, in MM cells.

4,101 View
25 Download

Alterating combination chemotherapy of cyclophosphamide, adriamycin, and vincristine(CAV) with etoposide and cisplatin(EP) in small cell lung cancer: Jong Wook Lee, Jin Hyoung Kang, Jong Youl Jin, Han Lim Moon, Young Seon Hong, Hoon Kyo Kim, Kyung Shik Lee, Dong Jip Kim, Sei Chul Yoon; J Korean Cancer Assoc. 1991;23(4):790-797.

Abstract PDF: No abstract available.

2,594 View
18 Download

Etoposide, adriamycin and cisplatin(EAP) chemotherapy in advanced gastric cancer: Jong Youl Jin, Kwang Moo Yoon, Hanlim Moon, Young Seon Hong, Hoon Kyo Kim, Kyung Shik Lee, Boo Sung Kim, Dong Jip Kim, Cho Hyun Park, In Chul Kim, Hyun Kwon Ha; J Korean Cancer Assoc. 1991;23(2):273-278.

Abstract PDF: No abstract available.

2,995 View
19 Download

Ketoconazole Treatment of Oral Candidiasis in Patients with Neoplastic Disease: Young Seon Hong, Dae Sik Hong, Sang Duck Cho, Hoon Kyo Kim, Kyung Shik Lee, Dong Jip Kim; J Korean Cancer Assoc. 1985;17(1):25-28.

Abstract PDF: The authors evaluated the effectiveness of ketoconazole for the treatment of oral candi- diasis by fungus culture in 10 patients with neoplastic disease. All patients received ketoconazole, 400 mg a day, and showed the initial response within 1 day and complete resolution of oral candidiasis within 4 days. Side effects were mild. In conclusion, the ketoconazole was effective, fast and convenient therapy for the treat- ment of oral candidiasis in patients with neoplastic disease, and showed mild hepatotoxicity.

2,620 View
14 Download

A Clinical Study on 45 Cases of Small and Non - Small Cell Lung Cancer: Woo Joong Kim, Choon Ik Song, Young Soo Jun, Han Lim Moon, Young Seon Hong, Hoon Kyo Kim, Ho Yun Kim, Kyung Shik Lee, Dong Jip Kim; J Korean Cancer Assoc. 1986;18(1):14-21.

Abstract PDF: A clinical study of 45 patients admitted with a diagnosis of small and non-small cell lung cancer to the Kang Nam St. Rlarys Hospital from NOV. 1982 to Dec. 1984 revealed the following results. 1) Among the 45 patients, 11 patients were classified as small cell cancer and 34 patients as non-small cell cancer with the highest incidence in the 6th to 8th decade. 2) The male/female ratio in small cell cancer and non-small cell cancer was 10: 1 and 2. 1: 1 respectively showing male predominance in small cell cancer. The smoker/mon-smoker ratio in small and non-small cell cancer was 4: 1 and 2.1: 1respectively showing smoker predominance in small cell cancer. 3) Coughing was the most common symptom in both small and non small cell cancer, but symptom due ta regional spread was not statistically different between two groups. 4) In the location of tumor, 72.7% of small cell cancer and 58.1% of non-small cell cancer were located in the central area showing more central distribution in small cell cancer. 5) Metastasis ta the bone and brain wzs more freguent in small cell cancer, but metastasis to the lymph node and bone marrow was more frequent in non-small cell cancer, although which was not statistically significant 6) 8 cases(72%) of small cell cancer and 17 cases(50M) of non-small cell cancer were diagn- ased by bronchoscopy showing higher rate of detection by broochoscopy in small cell cancer. And 2 cases(18.2%) of small cell cancer and 10 cases(29.4%) of non-small cell cancer were diagnosed by lymph node biopsy showing higher rate of detection by lymph node biapsy in non-small cell cancer. 7) Among the 5 cases of limited type-small cell cancer, partial and complete remission occurred in 3 cases(60%), 2 cases(40%) respectively showing mean survival of more than 14. 3 months. And among the 4 cases of extensive type-small cell cancer, 2 cases(50%) who showed partial remission lived 6 months and 2 cases(50%) who showed no response lived 3.5 months. 8) 29 cases(85.3%) of non-small cell cancer were stage g at the time of diagnosis in which 13 cases(81%) of squmaus cell cancer, 9 cases (82%) of adenocarcinoma and 7 cases(100%) of undifferentiated cell cancer were being included. 9) In the review of survival duration of non-small cell cancer, 10 cases(76. 9%) of response group showed mean survival of more than 7 months and R cases(23.1%) of non-response group lived 2. 2 months.

2,919 View
15 Download

Control of Cancer Chemotherapy-induced Nausea and Vomiting: Sung Min Cho, Jin Won Chang, Han Lim Moon, Young Seon Hong, Hoon Kyo Kim, Ho Yun Kim, Kyung Shik Lee, Dong Jip Kim; J Korean Cancer Assoc. 1986;18(1):35-41.

Abstract PDF: Nausea and vomiting are very unpleasant side effects and can be severe enough to inte- rrupt patients to take nutrition and to delay or stop therapy. Authors tried two combinations of antiemetic regimen with different drugs. In the first group of patients who were treated with cis-platin containing drugs, high doses of metoclopramide, 100 mg intravenously 30 minutes before and 1. 5, 3. 5, 5.5, and 8. 5 hours after chemotherapy and dexamethasone 20 mg intravenously RO minutes before chemotherapy were given on the first day. On the second and third day, metoclopramide 100 mg were given I V every 6 hours with 20 mg of oral thiethylperazine per day. The response rate was 91%, 82% and 100% on day 1,2 and 3, In the second group of patients treated with adriamycin containing regimen, 100 mg of dexamethasone I V every 6 hours and 20 mg of oral thiethy- Iperazine were administered on the first day 20 mg of oral thiethylpyrazine only on the second and third day. The response rate was 73%, 73% on day 1,2 and 3, Side effects such as dizziness(64%), sedation(32%) and anxiety(37%) were observed, but relatively tolerable. We concluded that adequate combinations of antimetics according to cancer chemotherape- utic agents improve control of cancer chemotherapy-induced nausea and vomiting and treat- ment-related side effects.

2,941 View
15 Download

The Additive Analgesic Effect of Ibuprofen ( Motrin ) in the Pain Control of the Cancer Patients: Min Sang Yi, Young Soo Jun, Han Lim Moon, Young Seon Hong, Hoon Kyo Kim, Ho Yun Kim, Kyung Shik Lee, Dong Jip Kim; J Korean Cancer Assoc. 1987;19(2):114-119.

Abstract PDF: We have studied the additive analgesic effect of Ibuprofen (Motrin) to other analgesics, such as Acetaminophen, Codeine, and Morphine Tincture, in 29 cancer patients with pain. Ibuprofen was administered 600 mg every 6 hour orally in addition to the other 3 drugs. Ibuprofen had additive analgesic effect only in mild or moderate pain (effectivity 77.8%) but not in severe pain. The drug was more effective in localized pain than in systemic pain (p<0.002), but the reported superiority of the drug in bone pain could not be confirmed. The adverse effects of Ibuprofen was minimal in frequency and severity. In twenty six of the 29 studied patients (89.7%), the pain could be controlled with these 4 drugs, alone or in combination.

2,762 View
17 Download

MACOP - B Chemthrapy for the Treatment of Malignant Lymphoma: Kyung Shik Lee, Hoon Kyo Kim, Young Seon Hong, Han Lim Moon, Je Ho Han, Chi Hong Kim; J Korean Cancer Assoc. 1990;22(1):112-116.

Abstract PDF: Between September 1987 and April 198S, 18 patients with advanced aggressive non-Hodgkin's lymphoma completed treatment with MACOP-B (methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin). Among them, 14 patients were evaluable for the response and toxicity. Twelve patients (86%) achieved a complete response and 2 patients (14%,) had a partial response. The most frequent toxicity was leukopenia. Thus, MACOP-B is an effective and safe treatment for advanced aggressive lymphoma.

2,597 View
15 Download

Serious Toxicities Induced by Vinblastine Overdose in a Patient with Relapsed Hodgkin's Disease: Sang Kook Han, Yong Joo Kim, Ji Youn Han, Jin Hyoung Kang, Han Lim Moon, Young Seon Hong, Hoon Kyo Kim, Kyung Shik Lee, Dong Jip Kim; J Korean Cancer Assoc. 1994;26(5):841-847.

Abstract PDF: Vinblastine, referred to as a vinka alkaloid, has been used as a component of the various chemotherapeutic regimens in the treatment of nonseminomatous testicular carcinoma, chorioearcinoma, non-small cell lung carcinoma, bladder cancer, head and neck cancer and cervical cancer. Vinblastine has been used as a main component of ABVD combination therapy for the patients with advanced Hodgkins disease who relapsed after therapy with the MOPP regimen. The major adverse effects of usual dosage of vinblatine are myelosuppression, nausea, vomiting, local effects(phlebitis, necrosis when extravasated), and peripheral and autonomic neuropathies. We experienced the life threatening toxicities including bone marrow suppression, oral mucositis, peripheral neuropathies and paralytic ileus in a 41-year-old male patient with re- lapsed Hodgkins disease who was errorneously treated with 50 mg of vinblastine. The patient was recovered completely with intensive supportive treatment.

2,435 View
20 Download

First
Prev
Page of 1
Next
Last

Search